Teva Pharmaceutical Industries (NYSE: TEVA) is considered a top growth stock under $25. Bank of America raised its price target to $24, expecting steady growth due to consistent performance. TEVA offers generic, specialty, and OTC products. Other AI stocks may offer better investment opportunities.